Recombinant human activated protein C: A system modulator of vascular function for treatment of severe sepsis

Critical Care Medicine

Volumn 29, Issue 7 SUPPL., 2001, Pages

  Grinnell, B W ^a   Joyce, D ^a   Vallet, B ^a   Ulevitch, R ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Activated protein C; Apoptosis; Coagulation; Inflammation; Sepsis; Thrombosis

Indexed keywords

ACTIVATED PROTEIN C; PROTEIN C; RECOMBINANT PROTEIN;

ANTICOAGULATION; CELL SURVIVAL; CONFERENCE PAPER; DISEASE SEVERITY; ENDOTHELIUM INJURY; GENE EXPRESSION PROFILING; GRAFT PATENCY; HUMAN; INFLAMMATORY DISEASE; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SEPSIS;

EID: 0034917319     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/00003246-200107001-00020     Document Type: Conference Paper

References (150)

1. Anti-inflammatory therapies to treat sepsis and septic shock: A reassessment
2. Anti-inflammatory therapies to treat sepsis and septic shock: A reassessment
3. Incidence, risk factors and outcome of severe sepsis and septic shock in adults
4. Therapies for sepsis emerging therapies for sepsis and septic shock
5. Epidemiology of sepsis syndrome in 8 academic medical centers
6. Has the mortality of septic shock changed with time?
7. The sirens' songs of confirmatory sepsis trials: Selection bias and sampling error
8. Age-specific incidence and outcome of sepsis in the US
9. Clinical Gram-positive sepsis: Does it fundamentally differ from Gram-negative bacterial sepsis?
10. Anatomy of an antibody, and related misadventures in developing an effective treatment for septic shock
11. A controlled trial of HA-lA in a canine model of Gram-negative septic shock
12. Effect of a recombinant dimeric tumor necrosis factor receptor on inflammatory responses to intravenous endotoxin in normal humans
13. How coagulation defects alter outcome in sepsis: Survival may depend on reversing procoagulant conditions
14. Therapy of sepsis: Why have we made such little progress?
15. Recombinant human activated protein C (rhAPC) produces a trend toward improvement in morbidity and 28 day survival in patients with severe sepsis
16. Recombinant human activated protein C (rhAPC) improves coagulation abnormalities, morbidity and 28-day mortality in patients with severe sepsis
17. Efficacy and safety of recombinant human activated protein C for severe sepsis
18. Molecular events that control the protein C anticoagulant pathway
19. Recombinant human protein C, protein S and thrombomodulin as antithrombotics
20. Antithrombotic and anti-inflammatory agents of the protein C anticoagulant pathway
21. An update on clinical and basic aspects of the protein C anticoagulant pathway
22. The protein C pathway: New insights
23. The protein C pathway
24. Inflammation, sepsis, and coagulation
25. Novel antithrombotics based on modulation of the protein C pathway
26. Transactivated expression of fully gamma-carboxylated recombinant human protein C, an antithrombotic factor
27. Expression and characterization of fully functional recombinant human protein C from the human kidney cell line 293
28. Posttranslational modifications of protein: Some problems left to solve
29. Characterization and novel purification of recombinant human protein C from three mammalian cell lines
30. Native and modified recombinant human protein C: Function secretion and posttranslational modifications
31. High-level expression of secreted proteins from cells adapted to serum-free suspension culture
32. A variant enhancer/regulatory region from a cloned human prototype BK virus genome
33. E1A-induced enhancer activity of the poly(dG-dT).poly(dA-dC) element (GT element) and interactions with a GT-specific nuclear factor
34. E1A-responsive mammalian host/vector system for the stable high-level expression of secreted proteins
35. A rapid and versatile method for the detection and isolation of mammalian cell lines secreting recombinant proteins
36. Amplification of multicistronic plasmids in the human 293 cell line and secretion of correctly processed recombinant human protein C
37. Viral transformation increases vitamin K-dependent gamma-carboxylation of glutamate
38. Posttranslational processing events in the secretion pathway of human protein C, a complex vitamin K-dependent antithrombotic factor
39. Effect of mutation of Asp71 on human protein C activation and function
40. Glycosylation of human protein C affects its secretion, processing, functional activities and activation by thrombin
41. Human protein C inhibits selectin-mediated cell adhesion: Role of unique fucosylated oligosaccharide
42. Inhibition of thrombus formation by activated recombinant protein C in a primate model of arterial athrombosis
43. Protein C activity by baseline predicts development of shock and 28 day mortality in patients with severe sepsis
44. Recombinant human activated protein C (rhAPC) improves coagulation abnormalities associated with severe sepsis
45. Inhibition of platelet-dependent thrombus formation by human activated protein C in a primate model
46. Antithrombotic effects of thrombin-induced activation of endogenous protein C in primates
47. Inhibitory effects of activated protein C and heparin on thrombotic arterial occlusion in rat mesenteric arteries
48. Inhibition of microarterial thrombosis by bovine activated protein C in a rabbit model
49. Preclinical pharmacology of activated protein C
50. Deep venous thrombosis in the baboon: An experimental model
51. Pharmacological profile of recombinant human activated protein C (LY203638) in a canine model of coronary artery thrombosis
52. Activated protein C: Antithrombotic properties and influence on fibrinolysis in an animal model
53. Enhancement of tissue plasminogen activator-induced fibrinolysis by activated protein C in endotoxin-treated rabbits
54. Anti-thrombotic effects of combining activated protein C and urokinase in nonhuman primates
55. Inhibitory effect of activated protein C on the experimental cerebral infarction in rabbits
56. Protein C activation following coronary artery occlusion in the in situ porcine heart
57. Replacement therapy with a monoclonal antibody purified protein C concentrate in newborns with severe congenital protein C deficiency
58. Purpura fulminans in severe congenital protein C deficiency: Monitoring of treatment with protein C concentrate
59. Treatment of patients with disseminated intravascular coagulation by protein C
60. Effect of protein C and activated protein C on coagulation and fibrinolysis in normal human subjects
61. Derangements of coagulation and fibrinolysis in critically ill patients with sepsis and septic shock
62. Purification and characterization of TAFI, a thrombin-activable fibrinolysis inhibitor
63. Protein C, protein S and C4b-binding protein in severe infection and septic shock
64. The pathogenesis of sepsis
65. Treating patients with severe sepsis
66. Alterations in coagulation and fibrinolysis during sepsis
67. The cytokine-mediated imbalance between coagulant and anticoagulant mechanisms in sepsis and endotoxaemia
68. Protein C levels as a prognostic indicator of outcome in sepsis and related diseases
69. Does programmed cell death (apoptosis) play a role in the development of multiple organ dysfunction in critically ill patients? A review and a theoretical framework
70. Endothelial apoptosis: Could it have a role in the pathogenesis and treatment of disease?
71. Sol Sherry lecture in thrombosis: How thrombin "talks" to cells: Molecular mechanisms and roles in vivo
72. Inflammation and thrombosis: Mutual regulation by protein C
73. Septic shock
74. Time course of hemostatic abnormalities in sepsis and its relation to outcome
75. The role of the endothelium in changes in procoagulant activity in sepsis
76. Disseminated intravascular coagulation
77. Role of the coagulation system in the local and systemic inflammatory response
78. Tumor necrosis factor suppresses transcription of the thrombomodulin gene in endothelial cells
79. Plasma thrombomodulin in health and diseases
80. Tumor necrosis factor leads to the internalization and degradation of thrombomodulin from the surface of bovine aortic endothelial cells in culture
81. Pathogenesis of disseminated intravascular coagulation in sepsis
82. Increase of plasminogen activator inhibitor levels predicts outcome of leukocytopenic patients with sepsis
83. The profibrinolytic effect of activated protein C in clots formed from plasma is TAFI-dependent
84. TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin-thromobmodulin complex
85. Protein C, protein S and C4b-binding protein in neonatal severe infection and septic shock
86. Septic shock, multiple organ failure and disseminated intravascular coagulation: Compared patterns of antithrombin III, protein C and protein S deficiencies
87. Protein C and S deficiency in severe infectious purpura of children: A collaborative study of 40 cases
88. Activation of the protein C pathway in acute sepsis
89. Coagulation activation and tissue necrosis in meningococcal septic shock: Severely reduced protein C levels predict a high mortality
90. Coagulation/fibrinolysis balance in septic shock related to cytokines and clinical state
91. Activation of the intrinsic pathway of coagulation in children with meningococcal septic shock
92. Factor VIIa and antithrombin III activity during severe sepsis and septic shock in neutropenic patients
93. The haematological manifestations of sepsis
94. Multiple organ dysfunction syndrome in bone marrow transplantation
95. Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon
96. DEFR-Factor Xa blocks disseminated intravascular coagulation initiated by E. coli without preventing shock or organ damage
97. Treatment of purpura fulminans in meningococcemia with protein C concentrate
98. Protein C in the treatment of coagulopathy in meningococcal disease
99. Successful treatment of meningococcal induced protein C deficiency/purpura fulminans in children with protein C concentrate and heparin
100. Epidemic meningococcemia and purpura fulminans with induced protein C deficiency
101. Protein C in the treatment of coagulopathy in meningococcal disease
102. Introduction: Are natural anti-coagulants candidates for modulating the inflammatory response to endotoxin?
103. Protein C prevents the coagulopathic and lethal effects of E. coli infusion in the baboon
104. Purpura fulminans and S. pneumonia sepsis with severe acquired protein C deficiency successfully treated with recombinant human activated protein C
105. Protein C substitution in sepsis-associated purpura fulminans
106. Severe acquired protein C deficiency in purpura fulminans associated with disseminated intravascular coagulation: Treatment with protein C concentrate
107. Protein C may be sepsis solution
108. Characterization of a functional thrombin receptor: Issues and opportunities
109. Immunobiology and therapeutic applications of protein C/protein S/thrombomodulin in human and experimental allotransplantation and xenotransplantation
110. Inhibition of LPS-induced activation of human monocytes by activated protein C (APC) occurs through a novel mechanism
111. Selective effects of protein C on activation of human monocytes by lipopolysaccharide, interferon-γ or PMA: Modulation of effects on CD11b and CD14 but not CD25 or CD54 induction
112. Selective inhibitory effects of the anticoagulant activated protein C on the responses of human mononuclear phagocytes to LPS, IFN-γ, or phorbol ester
113. The anticoagulants protein C and protein S display potent antiinflammatory and immunosuppressive effects relevant to transplant biology and therapy
114. Activated protein C inhibits tumor necrosis factor and macrophage migration inhibitory factor production in monocytes
115. Activated protein C inhibits lipopolysaccharide-induced nuclear translocation of nuclear factor κB (NF-κB) and tumour necrosis factor-α (TNF-α) production in the THP-1 monocytic cell line
116. Expression of endothelial leukocyte adhesion molecule-1 in septic but not traumatic/hypovolemic shock in the baboon
117. Soluble E-selectin is found in supernatants of activated endothelial cells and is elevated in the serum of patients with septic shock
118. Selectins
119. Induction of myocardial ELAM-1 by ischemia and reperfusion
120. Activated protein C attenuates endotoxin-induced pulmonary vascular injury by inhibiting activated leukocytes in rats
121. Activated protein C reduces ischemia/reperfusion-induced renal injury in rats by inhibiting leukocyte activation
122. Identification, cloning and regulation of a novel endothelial cell protein C/activated protein C receptor
123. Molecular cloning and expression of murine and bovine endothelial cell protein C/activated protein C receptor (EPCR)
124. Identification of functional endothelial protein C receptor in human plasma
125. The endothelial cell protein C receptor aids in host defense against Escherichia coli sepsis
126. Vascular-bed-specific hemostasis and hypercoagulable states
127. Human endothelium as a source of multi-functional cytokines: Molecular regulation and possible role in human disease
128. Vascular endothelial genes that are responsive to tumor necrosis factor-α in vitro are expressed in atherosclerotic lesions, including inhibitor of apoptosis protein-1, stannin, and two novel genes
129. Cell adhesion molecules: Selectins and integrins
130. Adaptive response of the endothelium to stress
131. Endothelial cells: Role in infection and inflammation
132. Neutrophil and endothelial cell interactions in sepsis: The role of adhesion molecules
133. Nuclear factor-κB: A pivotal transcription factor in chronic inflammatory diseases
134. NF-κB activation
135. Protective genes expressed in endothelial cells: A regulatory response to injury
136. Failure to regulate TNF-induced NFκB and cell death responses in A20-deficient mice
137. The new genomics: Global views of biology
138. Drug target validation and identification of secondary drug target effects using DNA microarrays
139. Genomic profiling of drug sensitivities via induced haploinsufficiency
140. Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors
141. Gene expression profile of antithrombotic protein C defines new mechanisms modulating inflammation and apoptosis
142. Leukocytosis and resistance to septic shock in intercellular adhesion molecule 1-deficient mice
143. Intercellular adhesion molecule-1-deficient mice are protected against ischemic renal injury
144. IAP family proteins: Suppressors of apoptosis
145. Cloning of human Bcl-2 homologue: Inflammatory cytokines induce human A1 in cultured endothelial cells
146. Changes in endoplasmic reticulum luminal environment affect cell sensitivity to apoptosis
147. Direct transactivation of the anti-apoptotic gene apolipoprotein J (clusterin) by B-MYB
148. Nitric oxide: An endothelial cell survival factor
149. Apoptosis in sepsis
150. Apoptotic vascular endothelial cells become procoagulant